Esperion Announces Publication of Phase 3 Data for Bempedoic Acid in the Journal of Clinical Lipidology
13 avr. 2022 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 13, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the publication of data from a pooled analysis of patients enrolled in four Phase 3 bempedoic acid...